MiR-155 promotes anaplastic thyroid cancer progression by directly targeting SOCS1.
Wei ZhangWenyue JiXudong ZhaoPublished in: BMC cancer (2019)
Aberrant miR-155/SOCS1 expression has been included in ATC progression: miR-155 overexpression leads to SOCS1 suppression and develops ATC progression. Thus, miR-155 has been considered to be an underlying therapeutic target for ATC.